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INTRODUCTION
The composition of saliva changes dynamically,
varying through the course of day, and in response
to physiological, psychological, and environmental
stimuli, as well as disease states. Because saliva
samples can be collected noninvasively, it is a suit-
able specimen for use in the diagnosis of disease
and for monitoring physiologic status. Salivary corti-
sone, endorphin, and amylase levels are markers
of stress (1 - 3) and salivary mRNAs are used as
markers of cancer (4). Recently, salivary proteomes
and transcriptomes were shown to change in rela-
tion to disease (5, 6).
The plasma membrane is a major barrier to water
transport. Aquaporins crucially regulate membrane
permeability to water. Aquaporin-5 (AQP5) is highly
expressed in salivary glands (7) and is important for
salivary secretion (8). In response to the activation
of M3 muscarinic acetylcholine receptors (mAChR)
and α1 -adrenoceptors, AQP5 is translocated to the
apical plasma membrane (APM) together with lipid
rafts (9). Some parts of AQP5 and the lipid rafts are
then released into the saliva (10).
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SALIVARY RELEASE OF AQP5
To investigate M3 mAChR agonist-induced secre-
tion of AQP5 into the saliva, we generated anti-
AQP5 antisera against recombinant human AQP5
protein (anti-hAQP5 antibody ; 10) and synthetic
C-terminus peptide of rat AQP5 (anti-rAQP5 an-
tibody ; 9). Confocal microscopy revealed that AQP5
is located in the apical plasma membrane (APM)
in the parotid glands in a diffuse pattern under rest-
ing conditions. After the injection of cevimeline, an
M3 mAChR agonist, AQP5 was predominantly asso-
ciated with the APM and localized in the APM and
lumen (Fig. 1). Immunohistochemical staining us-
ing anti-hAQP5 antibody (Fig. 1A) and anti-rAQP5
antibody (Fig. 1B in this review and Figs. 3B and 4B
in Ref 9) showed AQP5 in the lumen of the ducts,
suggesting that AQP5 was released into the saliva.
AQP5 LEVELS IN HUMAN SALIVA
To quantify the salivary AQP5 concentration, we
developed an enzyme-linked immunosorbent assay.
The amount of AQP5 in unstimulated saliva showed
a diurnal variation with secretion of high levels dur-
ing waking hours (1.590.24 ng/ml) and low lev-
els (0.630.12 ng/ml) during sleeping hours (10).
Salivary AQP5 levels decreased with an increase in
age and the decrease coincided with a decrease in
Fig. 1. Confocal immunofluorescence microscopic images of tissue slices showing changes in AQP5 in acinar and duct cells of rat
parotid glands treated with cevimeline.
The rat parotid gland was removed at 0 (a and c) and 6 (b and d) min after intravenous injection of cevimeline (5 mg/kg), rapidly
frozen with liquid nitrogen. Frozen sections (7 μm) were immediately fixed by prechilled ethanol. Sections were immunostained
with anti -human (h) AQP5 antibody (A) and anti -rat (r)AQP5 antibody (B) to detect AQP5 in acinar (-1) and duct (-2, -3, and -4)
cells using Alexa Fluor 488 (green). Nuclei were stained by propidium iodide (-1). Sections were also immunostained with anti -
flotillin-2 antibody using Alexa Fluor 568 (-2, -3, and -4). Bars, 10 μm.
The Journal of Medical Investigation Vol. 56 Supplement December 2009 351
the volume of unstimulated saliva secretion (10).
Cevimeline (i.e. , SNI-2011 or AF102B) induces
long-lasting salivation (11). Forty minutes after
cevimeline administration (30 mg/60 kg body
weight), salivary flow rates increased, reaching
maximum levels at 70 min, which then gradually
declined to the levels found in resting saliva at 160
min. The changes in salivary AQP5 levels after
cevimeline administration were parallel to the
changes in salivary flow rates. Salivary flow rates
were strongly correlated with the concentration of
salivary AQP5 (R=0.94, p0.001) and osmolality
was strongly and negatively correlated with the con-
centration of salivary AQP5 in the saliva provoked
by single administration of cevimeline (p.o. ; R=
-0.81, p0.001). These findings indicate that in hu-
mans of the same age changes in salivary AQP5 lev-
els can be used as an index of the salivary flow
rate and the effect of M3 mAChR agonists on sali-
vary glands.
ASSOCIATION OF AQP5 WITH LIPID RAFTS
IN HUMAN SALIVA
AQP5 localizes with lipid rafts in the cytoplasm
of acinar and duct cells in rat parotid glands, and
an increase in intracellular Ca2+concentration medi-
ates the effect of M3 mAChR agonists on the translo-
cation of AQP5 with lipid rafts to the APM, followed
by the dissociation of AQP5 from the lipid rafts to
non-rafts in the APM (9). The major portion of the
AQP5 of unstimulated saliva and cevimeline-stimu-
lated saliva was present in the supernatant frac-
tion (Sup) (Fig. 2A) obtained by centrifugation at
100,000 g for 60 min of Sup (1), indicating that sali-
vary AQP5 did not come from sloughed cells and
zymogen granules. Lipid rafts are insoluble in 1%
Triton X-100 at 4(12). As shown in Fig. 2B and
2C, 80% of the total amount of AQP5 in human sa-
liva was detected in the 1% Triton X-100-soluble
fraction (Sup(3)) (Fig. 2), whereas salivary GM1, a
Fig. 2. Association of AQP5 and GM1 in human saliva.
Saliva was collected for 5 min from healthy subjects ranging in age from 20 to 39 years before and 60 min after a single oral dose of
cevimeline (30 mg/60 kg of body weight). As shown in A, after centrifugation of saliva at 1000 g for 10 min, the resultant superna-
tant (Sup (1)) was centrifuged at 5600 g for 10 min to remove zymogen granules and their fragments (PPt). The resultant superna-
tant (Sup) was centrifuged at 100,000 g for 60 min to separate the membrane particles (PPt). The resultant supernatants (Sup) were
treated with 1% TX-100 to separate the TX-100-soluble (Sup (3)) and - insoluble (PPt (2)) fractions. These fractions were analyzed
by Western blotting with anti -human AQP5 and anti -GM1 antibodies (B). The intensity of chemiluminescence of AQP5 is expressed
in (C) as the relative intensity of the chemiluminescence of AQP5, with the corresponding value for Sup (1), which was obtained
from resting saliva and taken as 100%. The values and bars shown are the means of 4 to 6 separate experimentsS.E. A value of p
0.01 was considered significant. *0.01.
D. Wang, et al. Salivary AQP5 levels in human352
marker of lipid rafts, was detected in the 1% Triton
X-100-insoluble fraction (PPt(2)) (Fig. 2), indicat-
ing that AQP5 in human saliva was not associated
with lipid rafts.
SALIVARY AQP5 LEVELS IN DISEASE
It is well known that salivary flow rates are im-
paired in Type 1 diabetics (13) and Sjögren’s syn-
drome (14). In patients with diabetes mellitus or
Sjögren’s syndrome, the decrease in the salivary se-
cretion was concomitant with a decrease in AQP5
levels in the saliva (data not shown). In Alzheimer
patients treated with donepezil, salivary secretion
and salivary AQP5 levels were increased com-
pared with those from same-age subjects without
Alzheimer’s disease (data not shown).
CONCLUSION
Changes in the amount of salivary AQP5 may be
a useful index of the salivary flow rate and of the M3
mAChR agonist effect in the human salivary gland.
Salivary AQP5 levels may also be useful as a marker
of xerostomia.
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